Privacy PolicyPolitique de confidentialité

Press Release Communiqué de presse - January 17, 2019 17 January, 2019

Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial

January 17, 2019 9:00 a.m. EST

LONDON, ONTARIO – January 17, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase I/II trial of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes.

“We are pleased to report we are on track with patient enrollment in the Sernova Cell Pouch study for type 1 diabetes,” stated Dr. Piotr Witkowski, principal investigator and Director of the Pancreatic and Islet Transplant Program at University of Chicago School of Medicine. “The Cell Pouch System is designed to improve the quality of life of people with diabetes and this milestone marks an important step towards building further validation of Sernova’s innovative approach to diabetes treatment.”

Sernova is expecting to report preliminary safety data from this landmark clinical study in the first half of 2019 and preliminary efficacy data in the second half of 2019.

About the Study

The FDA allowed protocol is a Phase I/II non-randomized, open label, single arm, company-sponsored trial, where up to seven diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures including reduction in severe hypoglycemic events and HbA1c as well as survival of islets following transplant into the Cell Pouch. Study subjects will receive Sernova’s Cell Pouches including a small sentinel device implanted under the skin. Following a defined period to allow for the development of vascularized tissue chambers within the Cell Pouch, subjects will be stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, will be transplanted into the Cell Pouch.

The sentinel Cell Pouch will be removed after approximately 90 days to allow for an early assessment of islet survival in the device. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regard to the transplant of a second dose of purified islets. Patients will then be further followed to assess safety and efficacy for up to one year.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact (773) 702-2504.

About Diabetes

Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1 diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.

About the Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

Canada: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - December 20, 2018 20 December, 2018

Sernova Announces Enrollment of First Patient in U.S. Phase I/II Study of Cell Pouch for Treatment in Type 1 Diabetes

Initiating Treatment Phase of the Study at the University of Chicago

December 20, 2018 9:00 a.m. EST

LONDON, ONTARIO – December 20, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company announces the enrollment of the first patient in its Phase I/II trial of Sernova’s Cell Pouch for Clinical Islet Transplantation in type 1 diabetes.

“There is a real need for new treatment options in the field of type 1 diabetes,” said Dr. Piotr Witkowski, principal investigator and Director of the Pancreatic and Islet Transplant Program at University of Chicago School of Medicine. “Due to Sernova’s novel approach to demonstrate vascularization of the Cell Pouch and remarkable preclinical and first-in-human data, we are hopeful this study will provide a new functional therapeutic option in the treatment of patients with diabetes.” Dr. Witkowski added, “We expect completion of enrollment of the first patient cohort to be January 2019 and full enrollment to be completed by mid- 2019 as we continue to screen patients for the Sernova study.”

“The initiation of this Phase I/II trial is an important milestone for Sernova as our team looks to showcase our research and development efforts in diabetes on a clinical level at the University of Chicago, a world leader in regenerative medicine,” added Dr. Philip Toleikis, President and CEO of Sernova. “In our pilot first- in-human study, Sernova’s regenerative medicine approach, involving therapeutic cells within Sernova’s Cell Pouch, showed surviving vascularized islets able to produce all the hormones necessary to control blood glucose levels. Based on these positive initial results, we expect our therapeutic approach will demonstrate continued safety and therapeutic benefit to people suffering from type 1 diabetes.”

The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of 2019 and preliminary efficacy data in the second half of 2019.

About the Study

The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939 . For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact (773) 702-2504.

About Diabetes

Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1 diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes- related health complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.

About the Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

For investor inquiries and media inquiries in Canada: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - November 20, 2018 20 November, 2018

Sernova Highlights Achievements from the HemAcure Consortium in Developing a Novel Cell-Based Therapy for Hemophilia A

Source: Sernova Corp

November 20, 2018, 8:30 a.m. EST

LONDON, ONTARIO –November 20, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) a clinical-stage regenerative medicine company, highlights the achievements in developing a novel cell-based therapy in combination with Sernova’s Cell Pouch™ for treatment of Hemophilia A.

The therapeutic significance of this work supports the HemAcure Consortium’s concept that Factor VIII genetically corrected human cells from a blood sample of patients with Hemophilia A transplanted into the Cell Pouch can improve blood clotting.

“I am impressed with the achievements of this International Consortium within the limited time allowed. The technical teams worked closely together to complete this work in developing a first-in-world ex vivo gene therapy approach in an implanted vascularized medical device for the treatment of Hemophilia A.” said Dr. David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University, member of the Medical Advisory Board of the World Federation of Hemophilia, and HemAcure Scientific Advisory Board member.

A summary of the Consortium’s achievements are as follows:

• In blood donated from patients with Hemophilia A, endothelial outgrowth cells to be corrected for the Factor VIII gene were isolated and grown successfully in a specialized Good Manufacturing Process (cGMP) compliant medium developed by the Consortium.

• Using a human Factor VIII gene insertion technique, the cells were corrected and confirmed to produce Factor VIII.

• A preliminary experiment showed these cells could release Factor VIII in the blood over time and improve blood clotting in an animal model of Hemophilia A, in preparation for transplant into the Cell Pouch.

• The corrected cells were proven to be successfully replicated through a production scale-up process. Following amplification, these cells maintained their normal healthy behavior in producing Factor VIII. Additional safety metrics were achieved using established tests.

• The cells were then cryopreserved and shipped from the European partners to Sernova in North America where they were shown to remain healthy through quality control testing in preparation for transplantation.

• The Cell Pouch, manufactured under cGMP, and following implantation in the Hemophilia A animal model showed development of vascularized chambers suitable to receive the corrected cells.

• Following transplantation into the Cell Pouch in a Hemophilia A animal model, the patient’s Factor VIII corrected cells survived at three months (the duration of the study).

• Initial results showed Factor VIII released from the cells in the Cell Pouch was detected in blood and notably, showed improved clotting when compared to the Hemophilia A animal control which did not receive human corrected cells.

• The steps of the cell production process were documented towards development of the cGMP manufacturing process for the corrected cells for future clinical use. An Instructions-for-Use document was also developed for implantation of the cGMP Cell Pouch and transplantation of patient corrected Factor VIII producing cells applicable for future human testing in patients with Hemophilia A.

Sernova’s President & CEO, Dr. Philip Toleikis added, “These series of breakthroughs demonstrate success in correcting a Hemophilia A patient’s own cells to produce the missing Factor VIII protein and to improve blood clotting in an animal model of Hemophilia A in preparation for future human clinical trials.”

Technical results will continue to be presented by HemAcure Consortium members at scientific conferences and disseminated in scientific publications. Furthermore, steps are to complete cGMP manufacturing of the cells using the tools and methods developed by the Consortium, optimize dosing of cells in the Cell Pouch to achieve optimal therapeutic blood levels of Factor VIII, and conduct final formal studies in preparation for a first-in- human clinical study.

HemAcure’s webinar in which the consortium expert leaders present an overview of the findings is now available both on Sernova’s website at www.sernova.com and the HemAcure project website at www.hemacure.eu

About HemAcure

The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, Hemophilia A (caused by a genetic deficiency in clotting Factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union's Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Wuerzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario, Canada. This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 667421. The Consortium has been working together to provide sets of design and manufacturing protocols, based on current European GMP regulations to prepare an Investigational Medicinal Product Dossier (IMPD) for an Investigational Medicinal Product (IMP), composed of therapeutic cells and an implantable medical device (Sernova’s Cell Pouch). For more information, visit www.hemacure.eu

About Hemophilia A

People with Hemophilia A have prolonged abnormal bleeding as a result of trauma. Hemophilia A is the most common form of Hemophilia and is a genetic disorder caused by missing or defective FVIII, a blood clotting protein. Severe Hemophilia A occurs in about 60% of cases where the deficiency of FVIII is less than 1% of normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous change in the gene. According to the US Centers for Disease Control and Prevention, Hemophilia A occurs in about 1 in 5,000 births. Prolonged bleeding, in areas such as the brain, of a person with Hemophilia A, can be fatal. Prolonged bleeding in joints can cause inflammatory responses and permanent joint damage. Approximately 20,000 people in the United States, 2,500 in Canada and 10,000 in Europe have moderate to severe forms of Hemophilia A. Though there is no cure for the disease, Hemophilia A can be controlled with regular infusions of recombinant clotting FVIII. Annual worldwide costs for the treatment of the disease for each patient may range from $60,000 to $260,000 US for a total cost of approximately $15B per year.

About Horizon 2020 Programme

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over seven years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The project is funded as part of societal challenges “personalizing health and care” in a specific call about innovative treatments and technologies. New therapies, such as gene or cell therapies, often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving therapeutic scale production and cGMP standards at reasonable cost is often underestimated. The European Union aims to improve the development of advanced methods and devices for targeted and controlled delivery, and to bring these innovative treatments to the patient.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including Hemophilia A, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Danny Matthews, Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of the Hemophilia A program. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

HemAcure Webinar: https://youtu.be/ihyHefvJ8cQ

Press Release Communiqué de presse - November 09, 2018 9 November, 2018

Sernova Retains FronTier Flex for Canadian Investor Relations and Marketing

Source: Sernova Corp.

November 9, 2018 6:00 a.m. EST

LONDON, ONTARIO – November 9, 2018– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine company, announces that it has engaged FronTier Flex, an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and strategic marketing services.

Sernova President and CEO Dr. Philip Toleikis commented, "FronTier’s engagement falls within the expanded communications strategy Sernova is implementing to help investors and shareholders stay well-informed as we advance our new US diabetes Phase I/II clinical study and other programs. FronTier’s media experience will increase Sernova’s visibility and reach into the investment community through strategic messaging and investor outreach.”

Through their established network of financial industry professionals and marketing service providers, FronTier will assist the corporation by increasing market awareness for the corporation using a number of financial market communications initiatives, including facilitating in-person introductions for the corporation with institutional and retail brokers in Toronto and other financial capitals, and through media distribution on national television, radio and multiple online channels.

Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate remuneration of $87,000 plus expenses.

About Sernova Corp.

Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com

Philip Toleikis, Ph.D., President and CEO Tel: (519) 858-5184 info@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - November 06, 2018 6 November, 2018

Sernova Establishes Comprehensive North American Investor Relations and Communications Strategy

US Program to Focus on Raising Company’s Visibility Through Engagement of Solebury Trout

Source: Sernova Corp November 6, 2018 6:00 a.m. EST

LONDON, ONTARIO, November 6, 2018 – Sernova Corp (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine company, today announced it has engaged Solebury Trout ("Trout"), a New York- based investor relations and strategic advisory consultant serving life science companies.

Solebury Trout will develop and implement a comprehensive investor outreach program tailored to and in collaboration with Sernova that will include analyst and institutional and retail investor targeting/outreach, non- deal roadshows, corporate communications, and Key Opinion Leader (KOL) events in the chronic disease space.

“We have made significant progress in our diabetes program this year by advancing our US Phase I/II human clinical study of Sernova’s Cell Pouch™ with insulin-producing cells and by announcing the HemAcure Consortium’s achievements in developing a novel cell-based therapy for Hemophilia A. At this important juncture in the Company’s history, the engagement of Solebury Trout advances our strategic initiative to expand awareness of Sernova in the investment community, particularly among US institutional investors,” said Dr. Philip Toleikis, Chief Executive Officer of Sernova. “The team at Trout, with its capital market and institutional experience, brings capabilities that will enable us to present Sernova’s compelling story to a wide audience of investors, both in the U.S. and internationally.”

“Sernova has the potential to transform the diabetes, hemophilia and other chronic diseases treatment landscape with their disruptive regenerative medicine technologies and Solebury Trout will provide Sernova with its biotechnology and life sciences industry experience.” Stated Danny Matthews, Senior Associate at Solebury Trout.

Under the terms of the engagements, Solebury Trout has been retained for an extendable 12-month period for a monthly remuneration of US$16,500 plus direct expenses. Solebury Trout does not currently have any interest, either directly or indirectly, in the company. The agreement is subject to approval by the TSX Venture Exchange.

About Solebury Trout

Solebury Trout provides clients with senior counsel and execution on investor relations and corporate communications strategies. The firm's global reach extends through a network of offices in New York, Boston, Stamford and San Francisco, as well as consultants in the U.K., connecting clients with the right investors and media in all the major financial centers. A highly-experienced team of 60 senior professionals has expertise in investor relations, equity research, portfolio management, private equity, investment banking, journalism and corporate communications. Solebury Trout is affiliated with Solebury Capital, the leading equity capital markets advisory firm, and is a subsidiary of The PNC Financial Services Group, Inc.

About Sernova’s Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, proprietary stem cell- derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device, designed to eliminate concerns of fibrosis upon implantation incorporates with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for survival of insulin-producing cells in humans. Sernova is undertaking a Phase I/II clinical trial of the Cell Pouch with therapeutic cells for diabetes at the University of Chicago.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Danny Matthews, Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

Dominic Gray Communications Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - October 23, 2018 23 October, 2018

Sernova-HemAcure Consortium to Present Achievements in Development of a Regenerative Medicine Approach to Treat Hemophilia A

Source: Sernova Corp

October 23, 2018 6:00 a.m. EDT

LONDON, ONTARIO –October 23, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) a regenerative medicine company, announces that Dr. Philip Toleikis, Sernova’s President and CEO, along with the additional Horizon 2020 HemAcure Consortium Leaders, will present an overview of key achievements in developing a novel cell-based therapy for the treatment of Hemophilia A, in a publicly accessible webinar.

The webinar will include an introduction to the consortium, an overview of bleeding disorders with a focus on Hemophilia A, the innovative therapeutic approach HemAcure is developing as well as results and achievements to date. Participants are welcome to submit their questions during the webinar through the Q&A section. Questions that are left unanswered due to time constraint will be collected and answered in a written follow-up published on the HemAcure website.

“Sernova is proud to be amongst the innovators participating in this product development program involving Sernova’s platform technologies with the goal to treat hemophilia A patients. HemAcure is another great opportunity for Sernova to collaborate with international experts to advance next-generation regenerative medicine therapies,” stated Dr. Philip Toleikis, President and CEO of Sernova.

Webinar: Results in Fighting Haemophilia A Date/Time: Thursday October 25, 2018, 4:00 pm CEST (10:00 am ET) Speakers: Dr. Joris Braspenning (University Hospital Würzburg, Germany), Coordinator Prof. Dr. Antonia Follenzi (Università del Piemonte Orientale "Amedeo Avogadro,” Italy) Prof. Dr. Alexandra Stolzing (Loughborough University, UK) Dr. Philip Toleikis (Sernova Corp, Canada) Dipl.-Ing. Martin Zierau (Grünewald GmbH & Co. KG, Germany)

Host: Dr. Gabriele Wagner (ARTTIC, Germany)

To sign up for the Webinar, please visit bit.ly/2J63NYO or follow the instruction provided under Project News at www.hemacure.eu

The webinar will be made available on ARTTIC's YouTube channel, HemAcure’s website and Sernova’s website shortly after the event.

About HemAcure

The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, hemophilia A (caused by a genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union's Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Wuerzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario, Canada. The Consortium has been working together to provide sets of design and manufacturing protocols, based on current European GMP regulations to prepare an Investigational Medicinal Product Dossier (IMPD) for an Investigational Medicinal Product (IMP), composed of therapeutic cells and an implantable medical device (Sernova’s Cell Pouch™). For more information, visit www.hemacure.eu

About Sernova’s Cell Pouch™ Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, proprietary stem cell- derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device, designed to eliminate concerns of fibrosis upon implantation, incorporates with tissue forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for the survival of insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com

Philip Toleikis, Ph.D., President and CEO Tel: (519) 858-5184 info@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - July 23, 2018 23 July, 2018

Sernova Completes Oversubscribed Private Placement of $2,754,000

Source: Sernova Corp

July 23, 2018 6:00 a.m. EDT

LONDON, ONTARIO –July 23, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces it has completed a non-brokered private placement of $2.754 million, pursuant to which Sernova issued a total of 11,016,000 special warrants in two closing (July 13, 2018, and July 20, 2018).

“This oversubscribed placement was supported by retail and institutional investors who see Sernova rapidly advancing its regenerative medicine technologies on the world stage,” said Dr. Philip Toleikis, President and CEO of Sernova Corp.

Net proceeds from the private placement will be used to support funding of Sernova's FDA cleared US Phase I/II regenerative medicine clinical trial, “Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch™ for Clinical Islet Transplantation” and to advance corporate/academic collaborations utilizing the Company’s platform technology to treat diabetes, hemophilia and other serious disease conditions, as well as for general corporate purposes.

“With advancement of our programs, including our diabetes Phase I/II clinical trial, Sernova’s clinical development group has integrated the CTI and University of Chicago teams to advance a substantial regulatory package that has made the initiation of our first US clinical trial possible as we now advance patient enrollment and treatment with the resolute goal to improve the lives of people with diabetes,” said Toleikis.

Each Special Warrant will convert, for no additional consideration, into one Unit (Unit) on the earlier of the third business day after a receipt of a final prospectus qualifying the conversion is issued and the day after the expiry of the four-month statutory hold period. Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50 per share.

The private placement has received approval of the TSX Venture Exchange. Pursuant to applicable Canadian securities laws, the securities issued under the Private Placement are subject to a four-month hold period from the time of closing of the Private Placement. The hold periods for this Private Placement expire on November 14, 2018 and November 21, 2018.

The Company compensated finders by way of cash fees of $75,425 and 301,700 non- transferable finder warrants, each such finder warrant having the same terms as the Unit warrants.

About Sernova’s Cell Pouch™ Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, proprietary stem cell-derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device, designed to eliminate concerns of fibrosis upon implantation incorporates with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for survival of insulin- producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 Philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - July 15, 2018 15 July, 2018

Sernova Announces $2,000,000 First Closing of Private Placement

Due to Oversubscription, Offering Increased to $2,700,000

THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Source: Sernova Corp July 16, 2018, 6:00 a.m. EDT

LONDON, ONTARIO – July 16, 2018 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it closed $2,000,000 of its non-brokered private placement announced on June 26, 2018. In addition, as the Company has received over-subscriptions of $404,000, it is increasing the total amount of the non-brokered private placement offering of up to $2,700,000 for a total offering of 10,800,000 Special Warrants at $0.25 per Special Warrant. The Company plans to close the balance of the placement on July 20, 2018.

“We are pleased with the strong support from our longstanding as well as new investors including one of Canada’s most prestigious institutional funds who enthusiastically led this placement,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “We believe Sernova is the first in world to demonstrate survival and vascularization of human islets in a patented, implantable prevascularized device in our first assessment in humans and we are thrilled with our outstanding next-step clinical development program initiated at the University of Chicago for which this funding is primarily focussed.”

Net proceeds from the private placement will be used to support funding of Sernova's FDA cleared US Phase I/II regenerative medicine clinical trial and to advance corporate/academic collaborations utilizing the Company’s platform technology to treat diabetes, hemophilia and other serious disease conditions, as well as for general corporate purposes.

In the first closing on July 13, 2018, Sernova issued 8,000,000 Special Warrants at $0.25 per Special Warrant for gross proceeds of $2,000,000. Each Special Warrant will convert, for no additional consideration, into one Unit (“Unit”) on the earlier of the third business day after a receipt of a final prospectus qualifying the conversion is issued and the day after the expiry of the four-month statutory hold period. Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50 per share. Also, in respect of the first closing, the Company compensated finders by way of cash fees of $35,875 and 143,000 non-transferable finder warrants, each such finder Warrant will be exercisable into one share at $0.35 per share for a period of 24 months. The Company may also compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof. Completion of the private placement is subject the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.

About Sernova’s Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable prevascularized macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed to eliminate concerns of fibrosis upon implantation by incorporating with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Diabetes

Type1 Diabetes (T1D) is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 Philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - July 04, 2018 4 July, 2018

Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes

Source: Sernova Corp

July 5, 2018, 6:00 a.m. EDT

LONDON, ONTARIO –July 5, 2018 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with hypoglycemia unawareness.

Sernova’s initial clinical evaluation of the prevascularized Cell Pouch (TM) demonstrated biocompatibility and safety of the Cell Pouch as well as viability and vascularization of its transplanted insulin-producing islets, a first in world achievement in a prevascularized implantable medical device.

“This first-in-human work helped frame the design of Sernova’s new Phase I/II clinical protocol. Our clinical team at the University of Chicago is excited to initiate this trial of Sernova’s transformative technology,” said principal investigator, Dr. Piotr Witkowski, M.D., Ph.D.

“To support the clinical study’s timely execution under the highest quality standards, Sernova and CTI (Clinical Trial and Consulting), a well-respected clinical research organization with deep experience in the regenerative medicine field, are working closely with Dr. Witkowski’s team,” said Dr. Philip Toleikis, Sernova’s President and CEO.

The study is a Phase I/II, non-randomized, open label, single-arm, company-sponsored trial. Under the clinical leadership of Dr. Witkowski, University of Chicago Medicine, subjects with hypoglycemia unawareness enrolled in the study under informed consent will be implanted with the Cell Pouch. Following vascularized tissue development in the Cell Pouch, an initial dose of purified islets under strict release criteria will be transplanted into the Cell Pouch.

A sentinel pouch, also transplanted with islets, will be removed for an early assessment of the islet transplant. Subjects will be followed for safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Subjects will then be further followed for one year, with interim participants results released at periodic intervals consistent with an open-label study.

About Sernova’s Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable prevascularized macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed to eliminate concerns of fibrosis upon implantation by incorporating with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long- term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Diabetes

Type1 Diabetes (T1D) is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D- related health complications.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 Philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - June 25, 2018 25 June, 2018

Sernova Announces $2 Million Private Placement Financing

THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Source: Sernova Corp

June 26, 2018 6:00 a.m. EDT

LONDON, ONTARIO – June 26, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that the Company has secured a $1 million institutional lead order in connection with a proposed private placement (the “Offering”) of up to $2 million special warrants (“Special Warrants”) of the Company at a price of $0.25 per Special Warrant.

Each Special Warrant will convert, for no additional consideration, into one Unit (“Unit”) of the Company. Each Unit will consist of one common share and one common share purchase warrant (“Warrant”) of the Company. Each Warrant will be exercisable into one share at $0.35 per share for a period of 24 months, subject to abridgement of the exercise period if the 20 day volume weighted price of the Company’s shares exceeds $0.50 per share.

Net proceeds from the private placement will be used to fund Sernova's US-based Phase I/II diabetes clinical trial as well as potential collaborations utilizing our Cell Pouch System platform technologies and for general corporate purposes.

All securities issued in connection with the private placement will be subject to a statutory hold period of four months. The Company will compensate finders on a portion of the private placement, such compensation consisting of 7% in cash or 7% in finder warrants, or a combination thereof. Completion of the private placement is subject to the receipt of all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange.

The Company has agreed to file a final short form prospectus to qualify the distribution of the Units upon deemed conversion of the Special Warrants (the "Qualification") following the receipt of a final prospectus. If the Qualification does not occur within 4 months of closing, the Special Warrants will automatically convert into Units immediately following the expiry of the 4-month hold period. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Sernova’s Cell Pouch technologies

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell-derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device, designed to eliminate concerns of fibrosis upon implantation incorporates with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for survival of insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778\ ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.